Amag Pharmaceuticals ($AMAG) has received a dose of good news. Its second late-stage study of Feraheme as a treatment for iron deficiency anemia in a population of non-responders hit both primary endpoints, according to the company, laying the foundation for a supplemental NDA. Amag has been undergoing a turbulent time, bidding its CEO and a quarter of its work force goodbye after a proposed buyout of Allos Therapeutics ($ALTH) fell through amid some heated criticism. The biotech is also selling off its manufacturing facility in Cambridge, MA, as it circles its wagons around Feraheme. Story